ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

FTZ protects against cardiac hypertrophy and oxidative injury via microRNA-214 / SIRT3 signaling pathway

Zhang, Yue; Sun, Mengxian; Wang, Dongwei; Hu, Yaju; Wang, Ruonan; Diao, Hongtao; Shao, Xiaoqi; Li, Yun; Li, Xu; Leng, Mingyang; Wang, Lexun; Yan, Meiling; Rong, Xianglu; Guo, Jiao*广东药学院
Biomedicine and Pharmacotherapy2022-4DOI: 10.1016/j.biopha.2022.112696
5被引20阅读
引用收藏
分享

摘要

Background: Despite the fact that the initial hypertrophic response to ventricular pressure overload is thought to be compensatory, prolonged stress often leads to heart failure. Previous studies have shown that the FufangZhenzhu-Tiaozhi (FTZ) formula is beneficial for the treatment of dyslipidemia and hyperglycemia. However, the effects of FTZ on cardiac hypertrophy remain unclear. Objective: The aim of this study is to evaluate the protective effects of FTZ on cardiac hypertrophy and determine the underlying mechanisms. Methods: TAC was utilized to establish a cardiac hypertrophy animal model, and FTZ was given via gavage for four weeks. Next, echocardiographic measurements were made. The morphology of mouse cardiomyocytes was examined using H&E and WGA staining. In vitro, the neonatal cardiomyocytes were stimulated with angiotensin II (Ang II). In addition to measuring the size of cardiomyocytes, qRT-PCR and western blotting were conducted to measure cardiac stress markers and pathway. Results: According to our findings, FTZ alleviated cardiac hypertrophy in mice and cell models. Furthermore, expression of miR-214 was down-regulated following FTZ, whereas the effect of FTZ therapy was reversed using miR-214 transfection. Furthermore, the expression of Sirtuin 3 (SIRT3) was decreased in Ang II-induced oxidative damage, which was associated with a reduction in SOD-1, GPX1, and HO-1 and an increase in MDA, while SIRT3 expression was restored following FTZ treatment. Conclusions: Collectively, these findings indicate that FTZ is a protective factor for cardiac hypertrophy due to its regulation of the miR-214-SIRT3 axis, which suggests that FTZ may be a therapeutic target for cardiac hypertrophy.

学科与关键词

关键词
HypertrophyFTZMicroRNA-214SIRT3
相关
加载中…
  • The Traditional Chinese Medicine Formula FTZ Protects against Cardiac Fibrosis by Suppressing the TGFβ1-Smad2/3 Pathway
    Zhang, Yue; Wang, Dongwei; Wu, Kaili; Shao, Xiaoqi; Diao, Hongtao; Wang, Zhiying; Sun, Mengxian; Huang, Xueying; Li, Yun; Tang, Xinyuan; Yan, Meiling; Guo, Jiao*Evidence-based Complementary and Alternative Medicine, 2022, 2022: 5642307.被引 2
  • Targeting miR-30d reverses pathological cardiac hypertrophy
    Li, Jin; Sha, Zhao; Zhu, Xiaolan; Xu, Wanru; Yuan, Weilin; Yang, Tingting; Jin, Bing; Yan, Yuwei; Chen, Rui; Wang, Siqi; Yao, Jianhua; Xu, Jiahong; Wang, Zitong; Li, Guoping; Das, Saumya; Yang, Liming*; Xiao, Junjie*EBioMedicine, 2022, 81: 104108.被引 13
  • Fu Fang Zhen Zhu Tiao Zhi Capsules Protect against Myocardial Ischemia by Inhibiting Cardiomyocyte Pyroptosis
    Shao, Xiaoqi; Huang, Bingying; Tan, Huiling; Wang, Ruonan; Huang, Xueying; Diao, Hongtao; Cheng, Jiawen; Sun, Mengxian; Wang, Dongwei; Wu, Kaili; Yan, Meiling; Rong, Xianglu; Zhang, Yue; Guo, JiaoEvidence-based Complementary and Alternative Medicine, 2022, 2022: 4752360.
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomedicine and Pharmacotherapy
发表日期
2022-04
卷期
第 148 卷
页码
112696
DOI
10.1016/j.biopha.2022.112696
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
Key Project of National Natural Science Foundation of China [81830113]; National key Research and Development Program of China "Research on modernization of traditional Chinese medicine" [2018YFC1704200]; Major Basic and Applied Basic Research Projects of Guangdong Province of China [2019B030302005]

作者

  • Z

    Zhang, Yue (第一作者)

    guangdong pharmaceut univ

  • S

    Sun, Mengxian

    guangdong pharmaceut univ

查看全部 14 位作者收起作者
  • W

    Wang, Dongwei

    guangdong pharmaceut univ

  • H

    Hu, Yaju

    guangdong pharmaceut univ

  • W

    Wang, Ruonan

    guangdong pharmaceut univ

  • D

    Diao, Hongtao

    guangdong pharmaceut univ

  • S

    Shao, Xiaoqi

    guangdong pharmaceut univ

  • L

    Li, Yun

    guangdong pharmaceut univ

  • L

    Li, Xu

    guangdong pharmaceut univ

  • L

    Leng, Mingyang

    guangdong pharmaceut univ

  • W

    Wang, Lexun

    guangdong pharmaceut univ

  • Y

    Yan, Meiling

    guangdong pharmaceut univ

  • R

    Rong, Xianglu

    guangdong pharmaceut univ

  • G

    Guo, Jiao (通讯)

    guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417